Clinical trial
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
NCT00457171 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00457171 |
|---|---|
| Title | GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis |
| Official title | A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | GI-270384 |
| Enrollment | 16 |
| Start date | Dec 1, 2004 |
| First posted | Apr 5, 2007 |
| Last update posted | May 18, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: